摘要
目的探讨重组人血管内皮抑制素注射液抗血管生成联合化疗在非小细胞肺癌患者中的应用。方法选取2018年2月~2019年4月我院收治的58例非小细胞肺癌患者作为观察对象,将患者随机分为研究组(29例)与对照组(29例)。对照组患者采用常规化疗方案,研究组患者应用重组人血管内皮抑制素注射液抗血管生成联合化疗。比较两组患者的治疗总有效率、生活质量改善总有效率及不良反应总发生率。结果研究组患者的治疗总有效率为93.10%,对照组为55.17%,研究组的治疗总有效率高于对照组,差异有统计学意义(P<0.05)。研究组患者的生活质量改善总有效率为93.10%,对照组为62.07%,研究组的生活质量改善总有效率高于对照组,差异有统计学意义(P<0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论应用重组人血管内皮抑制素注射液抗血管生成联合化疗治疗非小细胞肺癌,可有效提升治疗效果,改善患者的生活质量,而且具有安全性。
Objective To explore the application of Recombinant Human Endostatin Injection anti-angiogenesis combined with chemotherapy in patients with non-small cell lung cancer.Methods A total of 58 patients with non-small cell lung cancer admitted to our hospital from February 2018 to April 2019 were selected as the observation objects.The patients were randomly divided into the study group(29 cases)and the control group(29 cases).The control group was treated with conventional chemotherapy.The study group was treated with Recombinant Human Endostatin Injection anti-angiogenesis combined with chemotherapy.The total effective rate of treatment,the total effective rate of improvement of life quality and the total incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the study group was 93.10%and 55.17%in the control group,which in the study group was higher than that in the control group,with statistically significant difference(P<0.05).The total effective rate of improvement of life quality in the study group was 93.10%and 62.07%in the control group,which in the study group was higher than that in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion The application of Recombinant Human Endostatin Injection anti-angiogenesis combined with chemotherapy in the treatment of non-small cell lung cancer can effectively increase the treatment effect,improve the quality of life of patients,and has safety.
作者
王艳茹
WANG Yan-ru(Department of Oncology,Anshan Cancer Hospital,Liaoning Province,Anshan114000,China)
出处
《中国当代医药》
2020年第31期100-102,共3页
China Modern Medicine
关键词
化疗
重组人血管内皮抑制素注射液抗血管生成
非小细胞肺癌
疗效
生活质量
Chemotherapy
Recombinant Human Endostatin Injection anti-angiogenesis
Non-small cell lung cancer
Efficacy
Quality of life
